BR112012021444A2 - polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. - Google Patents
polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.Info
- Publication number
- BR112012021444A2 BR112012021444A2 BR112012021444A BR112012021444A BR112012021444A2 BR 112012021444 A2 BR112012021444 A2 BR 112012021444A2 BR 112012021444 A BR112012021444 A BR 112012021444A BR 112012021444 A BR112012021444 A BR 112012021444A BR 112012021444 A2 BR112012021444 A2 BR 112012021444A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- polymer
- bile salts
- preparing
- pharmaceutical composition
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 6
- 150000001412 amines Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000003833 bile salt Substances 0.000 title abstract 3
- 229940093761 bile salts Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000008214 LDL Cholesterol Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 206010069703 Bile acid malabsorption Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/52—Amides or imides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F22/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides or nitriles thereof
- C08F22/36—Amides or imides
- C08F22/38—Amides
- C08F22/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/36—Amides or imides
- C08F222/38—Amides
- C08F222/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F232/00—Copolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
- C08F232/08—Copolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system having condensed rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30781410P | 2010-02-24 | 2010-02-24 | |
| US30781110P | 2010-02-24 | 2010-02-24 | |
| PCT/US2011/026099 WO2011106542A2 (en) | 2010-02-24 | 2011-02-24 | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012021444A2 true BR112012021444A2 (pt) | 2016-05-31 |
Family
ID=44310840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021444A BR112012021444A2 (pt) | 2010-02-24 | 2011-02-24 | polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9181364B2 (https=) |
| EP (2) | EP2539380B1 (https=) |
| JP (3) | JP5865847B2 (https=) |
| CN (2) | CN105017481B (https=) |
| AU (2) | AU2011220742B2 (https=) |
| BR (1) | BR112012021444A2 (https=) |
| CA (1) | CA2790999C (https=) |
| ES (1) | ES2549513T3 (https=) |
| WO (1) | WO2011106542A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011106548A1 (en) | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Amine polymers for use as bile acid sequestrants |
| WO2013087237A1 (en) * | 2011-12-13 | 2013-06-20 | Synthon Bv | Purification of sevelamer and related polyallylamines |
| CN104245745B (zh) | 2012-02-09 | 2017-03-29 | 生命技术公司 | 亲水性聚合物颗粒及其制备方法 |
| HK1220607A1 (zh) * | 2013-03-15 | 2017-05-12 | Genzyme Corporation | 晚期糖化终产物(age)前体的螯合剂 |
| EP3003327B1 (en) * | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| US10435528B2 (en) | 2013-09-17 | 2019-10-08 | Aquanano Llc | High-capacity anion exchange materials |
| CN103585632A (zh) * | 2013-11-19 | 2014-02-19 | 韩源平 | 胆汁酸螯合剂或/和维生素d在制备防治非酒精性脂肪性肝病药物中的应用 |
| ES2908142T3 (es) | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| WO2017004556A1 (en) | 2015-07-02 | 2017-01-05 | Life Technologies Corporation | Polymer substrates formed from carboxy functional acrylamide |
| EP3331499A4 (en) * | 2015-08-06 | 2019-04-10 | The Johns Hopkins University | COMPOSITION AND METHOD FOR THE TREATMENT OF METABOLISM DISEASES |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| CN106309436A (zh) * | 2016-07-25 | 2017-01-11 | 宁波大学 | 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途 |
| EP3564292B1 (en) | 2016-12-28 | 2021-06-16 | FUJIFILM Corporation | Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles |
| CN111225674A (zh) | 2017-10-16 | 2020-06-02 | 富士胶片株式会社 | 高磷血症治疗剂 |
| JP7018451B2 (ja) | 2017-10-16 | 2022-02-10 | 富士フイルム株式会社 | 高リン血症治療剤および粒子 |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| WO2020061430A1 (en) * | 2018-09-20 | 2020-03-26 | Glyscend, Inc. | Boronic acid polymers and methods of use |
| CN110511322B (zh) * | 2019-08-29 | 2020-10-02 | 西北大学 | 一种快速葡萄糖响应的互穿网络聚合物微凝胶及其制备方法 |
| MX2022003384A (es) | 2019-09-20 | 2022-06-27 | Glyscend Inc | Polimeros que contienen acido fenil boronico sustituido y metodos de uso. |
| WO2022131665A1 (ko) * | 2020-12-18 | 2022-06-23 | 한양대학교 산학협력단 | 신규 폴리플루오렌계 가교 공중합체 및 그 제조방법, 이를 이용한 알칼리 연료전지용 음이온교환막 |
| CN119730861A (zh) * | 2022-08-22 | 2025-03-28 | 中美华世通生物医药科技(武汉)股份有限公司 | 铵盐聚合物及其制备方法和作为胆汁酸螯合剂的用途 |
| WO2024220742A1 (en) * | 2023-04-20 | 2024-10-24 | Vasorx, Inc. | Conjugated polyethyleneimine compounds and compositions, and uses thereof for the treatment of atherosclerosis, cardiovascular, and lung disease |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236701A (en) | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
| JPH066667A (ja) | 1992-06-22 | 1994-01-14 | Canon Inc | ぶれ検出装置及びぶれ補正装置 |
| DK0580079T3 (da) | 1992-07-22 | 1997-06-30 | Hoechst Ag | Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser |
| ATE159262T1 (de) * | 1992-07-22 | 1997-11-15 | Hoechst Ag | Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff |
| US5556619A (en) | 1992-08-20 | 1996-09-17 | The Du Pont Merck Pharmaceutical Company | Crosslinked polymeric ammonium salts |
| US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| US5618530A (en) * | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5624963A (en) * | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5900475A (en) | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
| US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5414068A (en) | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| AU2446497A (en) | 1997-03-25 | 1998-10-20 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers combined with a calcium supplement for oral administration |
| US5925379A (en) | 1997-03-27 | 1999-07-20 | Geltex Pharmaceuticals, Inc. | Interpenetrating polymer networks for sequestration of bile acids |
| US6290947B1 (en) | 1997-09-19 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin-binding agents |
| JP3363143B2 (ja) * | 1998-10-12 | 2003-01-08 | 中外製薬株式会社 | リン酸結合性ポリマー粒子 |
| JP4749649B2 (ja) * | 1998-10-12 | 2011-08-17 | 中外製薬株式会社 | リン酸結合性ポリマー |
| US6482402B1 (en) | 1999-05-13 | 2002-11-19 | Geltex Pharmaceuticals, Inc. | Antimicrobial compositions and methods |
| US6180754B1 (en) * | 1999-09-03 | 2001-01-30 | The Dow Chemical Company | Process for producing cross-linked polyallylamine polymer |
| US6362266B1 (en) * | 1999-09-03 | 2002-03-26 | The Dow Chemical Company | Process for reducing cohesiveness of polyallylamine polymer gels during drying |
| EP1218388B1 (en) | 1999-09-08 | 2004-01-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Electronically tuned ligands |
| AR030176A1 (es) * | 1999-12-22 | 2003-08-13 | Procter & Gamble | Composicion de lavar ropa y/o de limpiar y/o para el cuidado de las telas y metodos para proveer una deposicion aumentada y una liberacion retardada del agente de beneficio sobre superficies tratadas |
| DE60212819T2 (de) * | 2001-04-18 | 2006-11-23 | Genzyme Corp., Cambridge | Salzformarme polyallylamine |
| CA2444028A1 (en) * | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Methods of treating syndrome x with aliphatic polyamines |
| DE10124387A1 (de) * | 2001-05-18 | 2002-11-28 | Basf Ag | Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien |
| US7135598B2 (en) | 2002-09-06 | 2006-11-14 | University Of Pittsburgh | N-vinylformamide derivatives, polymers formed therefrom and synthesis thereof |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US20050211624A1 (en) * | 2004-03-23 | 2005-09-29 | Vane Leland M | Hydrophilic cross-linked polymeric membranes and sorbents |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| US20060177415A1 (en) | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| JP4547620B2 (ja) * | 2004-12-02 | 2010-09-22 | 日東紡績株式会社 | 架橋アリルアミン類重合体の製造方法 |
| CA2601236A1 (en) * | 2005-03-16 | 2006-09-21 | Usv Limited | An improved process for the preparation of crosslinked polyallylamine polymer |
| US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| ES2382574T3 (es) * | 2006-05-18 | 2012-06-11 | Hercules Incorporated | Aductos de adición de Michael como aditivos para papel y fabricación de papel |
| US20090110907A1 (en) * | 2007-10-29 | 2009-04-30 | Jiang Dayue D | Membranes Based On Poly (Vinyl Alcohol-Co-Vinylamine) |
| JP2009179724A (ja) * | 2008-01-31 | 2009-08-13 | Toray Ind Inc | 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途 |
| WO2011106548A1 (en) | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Amine polymers for use as bile acid sequestrants |
| CN102858347B (zh) | 2010-02-24 | 2016-11-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的聚咪唑 |
-
2011
- 2011-02-24 CN CN201510370335.7A patent/CN105017481B/zh not_active Expired - Fee Related
- 2011-02-24 EP EP11707038.3A patent/EP2539380B1/en not_active Not-in-force
- 2011-02-24 WO PCT/US2011/026099 patent/WO2011106542A2/en not_active Ceased
- 2011-02-24 JP JP2012555152A patent/JP5865847B2/ja not_active Expired - Fee Related
- 2011-02-24 CN CN201180020656.4A patent/CN102858817B/zh not_active Expired - Fee Related
- 2011-02-24 BR BR112012021444A patent/BR112012021444A2/pt not_active Application Discontinuation
- 2011-02-24 CA CA2790999A patent/CA2790999C/en not_active Expired - Fee Related
- 2011-02-24 EP EP15180706.2A patent/EP2998329A3/en not_active Withdrawn
- 2011-02-24 ES ES11707038.3T patent/ES2549513T3/es active Active
- 2011-02-24 AU AU2011220742A patent/AU2011220742B2/en not_active Ceased
- 2011-02-24 US US13/581,049 patent/US9181364B2/en active Active
-
2014
- 2014-11-25 JP JP2014237462A patent/JP2015038225A/ja not_active Withdrawn
-
2015
- 2015-10-30 US US14/928,517 patent/US10272103B2/en active Active
-
2016
- 2016-05-25 AU AU2016203432A patent/AU2016203432B2/en not_active Ceased
- 2016-11-28 JP JP2016229926A patent/JP6247740B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6247740B2 (ja) | 2017-12-13 |
| AU2016203432B2 (en) | 2018-07-26 |
| US10272103B2 (en) | 2019-04-30 |
| JP5865847B2 (ja) | 2016-02-17 |
| CA2790999A1 (en) | 2011-09-01 |
| JP2013520561A (ja) | 2013-06-06 |
| US20160051576A1 (en) | 2016-02-25 |
| EP2539380A2 (en) | 2013-01-02 |
| JP2015038225A (ja) | 2015-02-26 |
| EP2998329A2 (en) | 2016-03-23 |
| EP2539380B1 (en) | 2015-08-19 |
| WO2011106542A3 (en) | 2011-11-10 |
| CN102858817A (zh) | 2013-01-02 |
| EP2998329A3 (en) | 2016-04-06 |
| AU2011220742B2 (en) | 2016-02-25 |
| CN102858817B (zh) | 2015-09-02 |
| US9181364B2 (en) | 2015-11-10 |
| CN105017481B (zh) | 2018-10-02 |
| AU2016203432A1 (en) | 2016-06-16 |
| CN105017481A (zh) | 2015-11-04 |
| ES2549513T3 (es) | 2015-10-28 |
| US20130022570A1 (en) | 2013-01-24 |
| WO2011106542A2 (en) | 2011-09-01 |
| CA2790999C (en) | 2019-05-14 |
| JP2017048398A (ja) | 2017-03-09 |
| AU2011220742A1 (en) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012021444A2 (pt) | polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. | |
| BR112012021448A2 (pt) | polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. | |
| BR112012021446A2 (pt) | polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. | |
| BRPI0509366B8 (pt) | composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica | |
| BRPI0810246A2 (pt) | Inibidores da dpp-iv incluindo o grupo beta-amino, método de preparação do mesmo e composição farmacêutica contendo o mesmo para prevenção e tratamento da diabetes ou obesidade. | |
| EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
| BR112012008282A2 (pt) | anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos | |
| CY1119010T1 (el) | Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη | |
| WO2013058833A8 (en) | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof | |
| EP2670434A2 (en) | Treatment of tauopathies | |
| BR112013032667A2 (pt) | polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra | |
| BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
| BR112017001623A2 (pt) | sais de berberina, sais ursodesoxicólico e combinações, métodos de preparação e aplicação dos mesmos | |
| EA201490852A1 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| JP2012507271A5 (https=) | ||
| EA200602210A1 (ru) | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение | |
| BRPI0908107A2 (pt) | composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente | |
| EA201001749A1 (ru) | Способ лечения недифференцированного артрита | |
| BRPI0820578A2 (pt) | Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças | |
| EA201171383A1 (ru) | Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение | |
| BRPI0921687A2 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
| MX374128B (es) | Formulaciones de moléculas de unión a antígeno de dominio sencillo. | |
| BR112013028523A2 (pt) | uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte | |
| EA200970255A1 (ru) | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение | |
| WO2008137236A3 (en) | Treatment of age-related macular degeneration using inhibitors of complement factor d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DAANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012,ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C08F 20/52 , C08F 22/38 , C08L 39/02 , C08F 26/02 , C08F 32/08 Ipc: A61K 31/785 (2006.01), C08F 22/38 (2006.01), C08L |
|
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |